<DOC>
	<DOCNO>NCT02193061</DOCNO>
	<brief_summary>Assess immunological behavior child 2 month age receive one seven anti-rotavirus vaccination program : Group 1 ( routine schedule two dos RV1 - Rotarix plus sterile water ) Group 2 ( routine schedule three dos RV5 - RotaTeq ) versus Group 3 ( one dose monovalent vaccine follow two dos pentavalent vaccine ) , Group 4 ( one dose pentavalent vaccine follow two dos monovalent vaccine ) , Group 5 ( two dos pentavalent vaccine follow dose monovalent vaccine ) , Group 6 ( one dose pentavalent vaccine follow dose monovalent vaccine dose pentavalent vaccine ) , Group 7 ( dose monovalent vaccine follow dose pentavalent vaccine dose monovalent vaccine ) child Mexico City . Secondary objectives - To describe number feature acute diarrheal disease ( ADD ) due rotavirus display seven prevention schedule . - To describe adverse event temporarily associate seven prevention schedule . Hypotheses The seroconversion percentages geometric mean titer ( GMT ) anti-rotavirus antibody Groups 3 , 4 , 5 , 6 7 inferior seroconversion percentage GMTs induce subject receive routine vaccination schedule two dos monovalent vaccine three dos pentavalent vaccine ( Groups 1 2 ) .</brief_summary>
	<brief_title>Randomized , Controlled Single-blind Clinical Study Assess Vaccine Interchangeability Between RV5 RV1 Using Seven Combined Anti-rotavirus Prevention Programs</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>The subject boy girl 2 month Â± one week old time first dose vaccine . The subject consider healthy base clinical history physical examination . The subject receive antirotavirus vaccine . The parent/tutor fully understand study 's procedure voluntarily accept participate sign write informed consent . The parent/tutor meet study 's requirement , attend program visit fill journal . Written inform consent sign parent/tutor procedure . The subject background serious allergic reaction vaccine 's component . The subject digestive tract malformation acute/chronic disease . The subject kind immunodeficiency include HIV . The subject suffers haematooncological disease . The subject treatment immunosuppressing medicine include prednisone two week . The subject receive gammaglobulin bloodderived product administration program study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>10 Weeks</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Rotavirus</keyword>
	<keyword>immunological behavior</keyword>
	<keyword>Rotarix</keyword>
	<keyword>RotaTeq</keyword>
	<keyword>vaccine interchangeability</keyword>
</DOC>